EBITDA Margin % is calculated as EBITDA divided by its Revenue. Abionyx Pharma's EBITDA for the
six
months ended in Dec. 2025 was €-3.09 Mil. Abionyx Pharma's Revenue for the
six
months ended in Dec. 2025 was €1.94 Mil. Therefore, Abionyx Pharma's EBITDA margin for the quarter that ended in Dec. 2025 was -159.05%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Abionyx Pharma EBITDA Margin % Related Terms
Abionyx Pharma EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Abionyx Pharma's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:609 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Abionyx Pharma's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abionyx Pharma EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abionyx Pharma's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Abionyx Pharma's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abionyx Pharma (FRA:609) has a EBITDA Margin % of -159.05% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Abionyx Pharma and its competitors. According to the industry distribution chart, Abionyx Pharma ranks #529 out of 945 companies in the Biotechnology industry, placing it in the top 56%.
Is Abionyx Pharma's EBITDA Margin % too high?
Abionyx Pharma's current EBITDA Margin % is -159.05%. Based on the distribution chart, Abionyx Pharma ranks #529 out of 945 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Abionyx Pharma has a GF Score™ of 15/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Abionyx Pharma's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abionyx Pharma ranks #529 out of 945 companies for EBITDA Margin %. This places Abionyx Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Abionyx Pharma and its competitors. Abionyx Pharma's current EBITDA Margin % is -159.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abionyx Pharma stock overvalued right now?
Based on GuruFocus' analysis, Abionyx Pharma (FRA:609) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.84, compared to a current price of €2.17 — trading 158.3% above its estimated fair value. The current EBITDA Margin % is -159.05%. Abionyx Pharma's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Abionyx Pharma (FRA:609), the current EBITDA Margin % is -159.05% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abionyx Pharma (FRA:609) Overvalued in 2026?
Based on GuruFocus' analysis, Abionyx Pharma stock appears to be overvalued.
The current stock price of €2.17 is trading 158.3% above its estimated GF Value™ of €0.84.
GuruFocus considers Abionyx Pharma to be Significantly Overvalued.
Key valuation signals for FRA:609:
EBITDA Margin %: -159.05%
GF Value™: €0.84 vs. price of €2.17 (158.3% above fair value)
No single metric tells the full story. See the FRA:609 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
15GF Score
Get the complete analysis for FRA:609
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:609 has been successfully added to your 
